Radioimmunotherapy (RIT) is a combination of radiation therapy and immunotherapy where a laboratory-produced molecule called a monoclonal antibody is introduced on to surface of cell to recognize and bind to cell. Monoclonal antibodies mimic the antibodies naturally produced by the body’s immune system that attack invading foreign substances. The two agents mostly used are Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) and Iodine-131 Tositumomab (Bexxar®) in radioimmunotherapy treatment.
Radioimmunotherapy (RIT) has become an essential advanced treatment for relapsed and/or refractory indolent NHL, with many studies reporting survival and quality-of-life benefits. As it is known that, Radioimmunotherapy (RIT) is a combination of radiation therapy and immunotherapy, where as a monoclonal antibody is paired with a radioactive material, or radiotracer. Radioimmunotherapy is performed by a radiologist, nuclear medicine physician or radiation oncologist. Radioimmunotherapy could result in reducing blood counts.
Related Journals of Radioimmunotherapy